NasdaqGS:PTCTBiotechs
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)?
In January 2026, PTC Therapeutics issued full-year 2026 guidance, projecting total product revenue of US$700 million to US$800 million, excluding Evrysdi royalty and collaboration revenue, while also reporting stronger-than-expected preliminary 2025 product and royalty results driven by Sephience.
The company coupled its outlook with updates on regulatory and pipeline progress, including FDA alignment on a Phase 3 Huntington’s trial for votoplam and continued engagement on vatiquinone and...